TRLV Stock Analysis: Trulieve Cannabis | US
Drug Manufacturers - Specialty & Generic | US, USA | Market Cap: 2.007m USD | 12M Return: 14.6% | CA89788C1041 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.9M
Qual. Beats: 2
Rev. Trend: 82.2%
Warnings
Tailwinds
Seasonality 0.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Trulieve Cannabis Corp. is a vertically integrated U.S. cannabis operator that cultivates, processes, manufactures, and distributes its own products through a network of company-owned dispensaries and home delivery. Its retail footprint spans eight states - Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania - supported by cultivation and processing facilities in seven of those markets. The company markets a diverse product portfolio across flowers, edibles, vapes, oral, topical, concentrates, and accessories under multiple proprietary brands including Avenue, Muse, Modern Flower, and Roll One.
The business model reflects the typical integrated structure of multi-state cannabis operators, combining wholesale production with direct-to-consumer retail to capture margin across the supply chain. Originally incorporated in 1940 as Schyan Exploration Inc., the company rebranded to Trulieve Cannabis Corp. in September 2018 and is headquartered in Tallahassee, Florida. It is classified within the consumer staples sector under the drug retail sub-industry, reflecting its dispensary-led revenue model.
- Florida adult-use vote drives upside to revenue and traffic
- Cannabis wholesale price compression pressures gross margins
- Ohio and Maryland expansion accelerates revenue diversification
| Net Income: -473.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 4.75 > 1.0 |
| NWC/Revenue: 41.24% < 20% (prev 49.52%; Δ -8.28% < -1%) |
| CFO/TA 0.12 > 3% & CFO 244.8m > Net Income -473.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (192.7m) vs 12m ago 0.79% < -2% |
| Gross Margin: 59.47% > 18% (prev 60.32%; Δ -0.85% > 0.5%) |
| Asset Turnover: 45.57% > 50% (prev 40.61%; Δ 4.96% > 0%) |
| Interest Coverage Ratio: -4.73 > 6 (EBIT TTM -269.1m / Interest Expense TTM 56.8m) |
| A: 0.23 (Total Current Assets 564.8m - Total Current Liabilities 95.1m) / Total Assets 2.08b |
| B: -0.63 (Retained Earnings -1.32b / Total Assets 2.08b) |
| C: -0.11 (EBIT TTM -269.1m / Avg Total Assets 2.50b) |
| D: 0.59 (Book Value of Equity 767.5m / Total Liabilities 1.31b) |
| Altman-Z'' = -0.69 = B |
| DSRI: 1.33 (Receivables 27.1m/21.2m, Revenue 1.14b/1.19b) |
| GMI: 1.01 (GM 60.32% / 59.47%) |
| AQI: 0.83 (AQ_t 0.38 / AQ_t-1 0.45) |
| SGI: 0.96 (Revenue 1.14b / 1.19b) |
| TATA: -0.35 (NI -473.4m - CFO 244.8m) / TA 2.08b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of November 03, 2026, the stock is trading at USD 11.10 with a total of 1,987,367 shares traded. Over the past week, the price has changed by +2.59%, over one month by +3.54%, over three months by +29.07% and over the past year by +14.55%.
Current recommended Stop Loss: 9.40 (which is 15.3% or 2.6 ATR below the current price).
Trulieve Cannabis has received a consensus analysts rating of 4.86. Therefore, it is recommended to buy TRLV.
- StrongBuy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.2 | 63.8% |
P/E Forward = 22.8833
P/S = 1.7616
P/B = 3.1289
Revenue TTM = 1.14b USD
EBIT TTM = -269.1m USD
EBITDA TTM = -99.2m USD
Long Term Debt = 285.2m USD (from longTermDebt, last quarter)
Short Term Debt = 26.2m USD (from shortTermDebt, last quarter)
Debt = 865.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 287.9m
Net Debt = 539.7m USD (calculated: Debt 865.1m - CCE 325.4m)
Enterprise Value = 2.55b USD (2.01b + Debt 865.1m - CCE 325.4m)
Interest Coverage Ratio = -4.73 (Ebit TTM -269.1m / Interest Expense TTM 56.8m)
EV/FCF = 13.63x (Enterprise Value 2.55b / FCF TTM 186.8m)
FCF Yield = 7.34% (FCF TTM 186.8m / Enterprise Value 2.55b)
FCF Margin = 16.40% (FCF TTM 186.8m / Revenue TTM 1.14b)
Net Margin = -41.56% (Net Income TTM -473.4m / Revenue TTM 1.14b)
Gross Margin = 59.47% ((Revenue TTM 1.14b - Cost of Revenue TTM 461.6m) / Revenue TTM)
Gross Margin QoQ = 59.90% (prev 59.31%)
Tobins Q-Ratio = 1.23 (Enterprise Value 2.55b / Total Assets 2.08b)
Interest Expense / Debt = 6.57% (Interest Expense 56.8m / Debt 865.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -212.6m (EBIT -269.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.94 (Total Current Assets 564.8m / Total Current Liabilities 95.1m)
Debt / Equity = 1.13 (Debt 865.1m / totalStockholderEquity, last quarter 767.5m)
Debt / EBITDA = -5.44 (negative EBITDA) (Net Debt 539.7m / EBITDA -99.2m)
Debt / FCF = 2.89 (Net Debt 539.7m / FCF TTM 186.8m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -18.94% (Net Income -473.4m / Total Assets 2.08b)
RoE = -44.03% (Net Income TTM -473.4m / Total Stockholder Equity 1.08b)
RoCE = -19.78% (EBIT -269.1m / Capital Employed (Equity 1.08b + L.T.Debt 285.2m))
RoIC = -10.89% (negative operating profit) (NOPAT -212.6m / Invested Capital 1.95b)
WACC = 2.93% (E(2.01b)/V(2.87b) * Re(1.95%) + D(865.1m)/V(2.87b) * Rd(6.57%) * (1-Tc(0.21)))
Discount Rate = 1.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 3.54%
Shares (quarterly) Correlation: 58.40 | Cagr: 0.68%
[DCF] Terminal Value 77.97% ; FCFF base≈161.6m ; Y1≈185.3m ; Y5≈272.7m
[DCF] Fair Price = 20.94 (EV 4.10b - Net Debt 539.7m = Equity 3.56b / Shares 170.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.39 | # QB: 2
Revenue Correlation: 82.21 | Revenue CAGR: 2.28% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.07 | Chg30d=+0.00% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.82 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=-198.8% | GrowthRev=-14.6%
EPS next Year (2027-12-31): EPS=0.56 | Chg30d=+0.18% | Revisions=+25% | GrowthEPS=+130.2% | GrowthRev=-7.2%
[Analyst] Revisions Ratio: -12% (up=2, down=3)